Skip to content

A study to evaluate efficacy of Unani Compound Formulations in Benign Prostatic Hyperplasia

To evaluate the efficacy of Unani Compound Formulations in the management of Azm-e-Ghudda-e-Madhi (Benign Prostatic Hyperplasia) - BPH

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072872
Enrollment
30
Registered
2024-08-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Prepared Unani Formulation include the following ingredients: Shorah Qalmi (Potassium Nitrate) 3gm, Tukhm-e-Neel (Ipomoea nil) 12gm and Kafoor (Cinnamomum camphora) 3gm.: Topical Appli

Sponsors

State Takmeel uttib College and Hospital Lucknow
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male patients complaining of LUTS Clinically diagnosed patients of BPH PSA level less than 10ng/ml USG findings (weight less than 60gm and PVR less than 200cc) Male patients willing to give written informed consent

Exclusion criteria

Exclusion criteria: Patients with severe cardiac and pulmonary diseases Patients with hepatic and renal diseases Uncontrolled Hypertension Uncontrolled Diabetes Mellitus Vesical Calculus Acute retention of urine Neurogenic bladder Abscess and Carcinoma of the prostate PSA level equal or more than 10ng/ml USG findings (weight equal or more than 60gm and PVR equal or more than 200cc) Male patients who not willing to give consent Mentally retarded patients

Design outcomes

Primary

MeasureTime frame
Poor stream of urine Hesitancy during micturition Terminal dribbling Feeling of incomplete emptying of urinary bladder Frequency of urine Nocturia Urgency of urineTimepoint: 0, 7th, 14th, 21st, 28th, 35th and 42nd day

Secondary

MeasureTime frame
Prostate Specific Antigen (PSA) USG (Abdomenopelvic) including Full Bladder Volume (FBV) and Residual Urine Volume (RUV)Timepoint: 0 and 42nd day

Countries

India

Contacts

Public ContactDr Abdul Quavi

Department of Ain Uzn Anaf wa Halaq State Takmeel uttib College and Hospital

drsafiyalokhande@gmail.com7985186938

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026